HARP - Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition | Benzinga

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65^th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.

Details of the ASH presentation are as follows:

Title: Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
Publication Number: 1012
Presenter: Sumit Madan, M.D., Banner MD Anderson Cancer Center
Session Name: 653. Multiple Myeloma: Prospective Therapeutics Trials: Relapsed and Refractory Myeloma
Session Room: Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD
Date: Monday, December 11, 2023
Time: Viewing – 4:30 to 6:00 p.m. PT / 7:30 to 9:00 p.m. ET, Presentation – 5:15 p.m. PT / 8:15 p.m. ET

The presentation will also be available on Harpoon's website following the session.

For more details about the ASH Annual Meeting, please visit:

Full story available on Benzinga.com